MRNS Marinus Pharmaceuticals Inc
12,465
$1.43
$0.14
(8.92%)
| Watchers | 12,465 |
| 52-Wk Low | $1.11 |
| 52-Wk High | $11.26 |
| Market Cap | $85.79M |
| Volume | 2.4M |
| 52-Wk High | $11.26 |
| 52-Wk Low | $1.11 |
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsBusiness Wire • about 12 hours ago
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and...
Share to Feed
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release...
Marinus Pharmaceuticals provides updates on Phase 3 RAISE trial for refractory status epilepticus treatment with IV ganaxolone. With enrollment completion expected, topline results are anticipated by...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement...
Investors considering a purchase of Marinus Pharmaceuticals Inc (MRNS) stock, but tentative about paying the going market price of 8.95/share, might benefit from considering selling puts among...
This indicator may be signaling that MRNS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This is a Bullish indicator signaling MRNS's price could rise from here. Traders may explore going long the stock or buying call options...
As a company grounded in scientific research, we will vigorously defend our patents, said Marinus CEO Dr. Scott Braunstein...